Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Carolyn M Millar, Priyanka Raheja, Allison P Wheeler, Shrinath Kshirsagar, Christian Schoergenhofer, Nicoletta C Machin, Cihan Ay, Almudena Tercero, Hayley Lane, Christopher J Horvath, Sandip Panicker, Gary Patou, Benjamin Kim, Savita Rangarajan

Blood (2024) 144 (Supplement 1): 3981.

https://doi.org/10.1182/blood-2024-208020

Published: 2024

Journal Articles

Pre-Clinical Characterization of VGA039, an Anti-Protein S Monoclonal Antibody Being Developed As a Universal Hemostatic Agent for Various Bleeding Disorders

Lilley Leong, Tony Byun, Benjamin Kim, Ian Huck, Abel Silva, Joanne Chan, Young Cho, John Liu, Christopher J. Horvath, Stephen J. Moore, Sandip Panicker

Blood (2022) 140 (Supplement 1): 1666–1667.

https://doi.org/10.1182/blood-2022-170245

Published: 2022

Journal Articles

Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes

Eileen Rose, Stephen J. Moore, Allen Cai, Alina He, Ian Huck, Jen Razo, Laurie Wong, Joanne Chan, Christopher J. Horvath, John Liu, Sandip Panicker

Blood (2022) 140 (Supplement 1): 8318–8319.

https://doi.org/10.1182/blood-2022-168013

Published: 2022

Journal Articles

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

James B Rottman, DVM, PhD DACVP, Kenneth Ganley, BS, Brenna Daly, BS, Holly M. Horton, PhD, Kevin M. Friedman, Molly Perkins, PhD, Shannon Grande, PhD, Claire J Rhodes, BS, Richard A. Morgan, PhD, Christopher J. Horvath, DVM, MS, DACVP

Blood (2017) 130 (Supplement 1): 4450.

https://doi.org/10.1182/blood.V130.Suppl_1.4450.4450

Published: 2017

Journal Articles

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil., Shannon Grande, PhD, Amanda Hamel, BS, Holly M. Horton, PhD, Tracy E. Garrett, BA, Sara M. Miller, Howard J. Latimer, IV, BS, Christopher J. Horvath, DVM, MS, DACVP, Michael Kuczewski, MS, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 1893.

https://doi.org/10.1182/blood.V126.23.1893.1893

Published: 2015

Journal Articles

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Alena A. Chekmasova, PhD, Holly M. Horton, PhD, Tracy E. Garrett, BA, John W. Evans, PhD, Johanna Griecci, BS, Amanda Hamel, BS, Howard J. Latimer, IV, BS, Stacie L. Seidel, MA, Byoung Y. Ryu, PhD, Michael Kuczewski, MS, Christopher J. Horvath, DVM, MS, DACVP, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 3094.

https://doi.org/10.1182/blood.V126.23.3094.3094

Published: 2015

Journal Articles

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, Michela Sica, Luigi del Vecchio, Christopher J. Horvath, Masha Fridkis-Hareli, Carmine Selleri, Margaret A. Lindorfer, Ronald P. Taylor, Lucio Luzzatto, V. Michael Holers

Blood (2012) 119 (26): 6307–6316.

https://doi.org/10.1182/blood-2011-12-398792

Published: 2012

Includes: Supplemental data

Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers

Blood (2011) 118 (17): 4705–4713.

https://doi.org/10.1182/blood-2011-06-359646

Published: 2011

Includes: Supplemental data

Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD

Blood (2010) 116 (21): 637.

https://doi.org/10.1182/blood.V116.21.637.637

Published: 2010

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

NARROW

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Pre-Clinical Characterization of VGA039, an Anti-Protein S Monoclonal Antibody Being Developed As a Universal Hemostatic Agent for Various Bleeding Disorders

Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only